Kylo-11 or matched placebo

Phase 2

KKylonova (Xiamen) Biopharma co., LTD.

Kylo-11 or matched placebo is one of 2 therapeutic programs targeting Lipoprotein Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lipoprotein DisorderRecruiting

Lipoprotein DisorderPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Lipoprotein Disorder

#DrugCompanyPhaseTrials

HRS-5346

SShandong Suncadia Medicine Co., Ltd.

Phase 2

2 2

Kylo-11 or matched placebo

KKylonova (Xiamen) Biopharma co., LTD.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Lipoprotein Disorder

NCT07327840

Clinical

Trials by Indication[1]

Lipoprotein Disorder1 trial

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

Recruiting·KKylonova (Xiamen) Biopharma co., LTD.·Phase 2·NCT07327840·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kylo-11 or matched placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Kylo-11 or matched placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kylonova (Xiamen) Biopharma co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: KKylonova (Xiamen) Biopharma co., LTD.

Kylo-11 or matched placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lipoprotein Disorder1 trial

References

Drug Info

Quick Facts

Related News